Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine
Withdrawn
The purpose of this research study is to compare the antidepressant effect of lithium versus placebo in adults receiving ketamine. Lithium is available commercially for depression; ketamine is available commercially and can help the symptoms of depression; however, it has not been approved by the U.S. Food and Drug Administration (FDA) for this use. The FDA has allowed the use of this drug in this research study.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
08/14/2018
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Treatment Resistant Depression
Sub-dissociative Ketamine for the Management of Acute Pediatric Pain
Completed
The proposed trial is a prospective, double blinded, randomized control trial with the primary aim of determining whether a single, sub-dissociative dose of ketamine will decrease the total narcotic requirements of pediatric patients requiring intravenous analgesia in an urban emergency department (ED) compared to a group of patients who receive morphine alone for pain management. Patients are randomized to receive either a single bolus of ketamine (0.3 mg/kg) or a single bolus of morphine (0.05... Read More
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
06/05/2018
Locations: Regions Hospital, Saint Paul, Minnesota
Conditions: Pain
Ketamine for Depression and Suicide Risk
Completed
The purpose of this research study was to find out if the medication known as ketamine could help the symptoms of depression. This drug is approved by the U.S. Food and Drug Administration (FDA) as an anesthetic agent; however, it is not approved for use in depression treatment. The FDA allowed the use of this drug in this research study.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/10/2017
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Depression, Suicide
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
Completed
RATIONALE: Baclofen-amitriptyline-ketamine (BAK) gel may lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether BAK gel is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy . PURPOSE: This randomized phase III trial is studying BAK gel to see how well it works compared with a placebo in treating peripheral neuropathy caused by chemotherapy in patients with cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2017
Locations: MeritCare Bemidji, Bemidji, Minnesota +18 locations
Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Low Dose Ketamine as an Adjunct to Fentanyl in Outpatient Tonsillectomy
Completed
Comparing patients receiving subanesthetic doses of Ketamine vs placebo to see if it can reduce narcotic needs for patients receiving a tonsillectomy and adenoidectomy
Gender:
ALL
Ages:
Between 3 years and 12 years
Trial Updated:
06/12/2017
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Pain
Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients
Completed
RATIONALE: Topical cream containing amitriptyline and ketamine may help relieve pain, numbness, tingling, and other symptoms of peripheral neuropathy. It is not yet known whether topical amitriptyline and ketamine cream is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy. PURPOSE: This randomized phase III trial is studying the side effects and how well topical amitriptyline and ketamine cream work compared with a placebo in treating peripheral neuropathy c... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/13/2015
Locations: CCOP - Metro-Minnesota, St. Louis Park, Minnesota
Conditions: Neurotoxicity, Pain, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
Randomized Clinical Trial of Propofol, 1:1 and 4:1 Combination of Propofol and Ketamine for Procedural Sedation
Completed
This will be a randomized trial of propofol versus the combination of propofol and ketamine for procedural sedation for procedures in the Emergency Department (ED). Propofol produces sedation, hypnosis, and dense amnesia, and is commonly used in the ED at Hennepin County Medical Center (HCMC) for procedural sedation. Ketamine is a dissociative anesthetic that is also frequently used in the ED in children and sometimes in adults. It has been proposed that by combining the two agents, the negative... Read More
Gender:
ALL
Ages:
1 year and above
Trial Updated:
06/15/2015
Locations: Hennepin County Medical Center, Minneapolis, Minnesota
Conditions: Procedural Sedation
Ketamine Anesthesia in Electroconvulsive Therapy
Completed
Does the use of ketamine as the anesthetic medication in electroconvulsive therapy (ECT) accelerate the antidepressant effect of ECT? The study hypothesis was that depressed subjects receiving ECT with ketamine as the anesthetic agent would demonstrate a faster rate of improvement, defined as lower depression ratings after the second ECT than depressed patients receiving ECT with the usual anesthetic agent.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2013
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Depression
Propofol Versus Ketamine for Moderate Procedural Sedation in the Emergency Department (ED)
Completed
This study is a clinical trial of moderate sedation with propofol versus moderate sedation with ketamine for procedural sedation in the Emergency Department.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2012
Locations: Hennepin County Medical Center, Minneapolis, Minnesota
Conditions: Sedation
Ketamine Frequency Treatment for Major Depressive Disorder
Withdrawn
Depression is a wide spread illness. Depression contributes most significantly to national health care costs. While the number and types of treatments used for depression have expanded over the years, even with an increased range of options, the response rate, defined as the number of subjects who have a 50% reduction in depressive symptoms, is estimated to be around 65%. This randomized clinical trial will examine the frequency of treatment with ketamine in patients with treatment-resistant de... Read More
Gender:
ALL
Ages:
Between 30 years and 65 years
Trial Updated:
06/03/2011
Locations: St. Mary's Duluth Clinic Health System, Duluth, Minnesota
Conditions: Treatment Resistant Depression